Genticel (Euronext Paris and Brussels: FR0011790542 – GTCL), a French biotechnology company and a leading developer of therapeutic vaccines, announced today its participation in the “French Life Sciences Days” to be held in New York on June 25 & 26, 2014.

During this event, Genticel, and other French Biotech and Medtech companies listed on the regulated markets of Euronext, will introduce the company to American specialized investors. This new initiative of France Biotech aims to strengthen the bond between French publicly listed companies and American investors and reinforce the interest in companies listed on the Euronext stock exchange.

During this occasion, Benedikt Timmerman, Founder & CEO of Genticel, will present ProCervix, a “first-in-class” therapeutic vaccine, now in phase II in Europe. ProCervix is designed to provide a therapeutic solution for women with highly oncogenic strains of human papillomavirus (HPV) before high-grade lesions or cancer occur.

“U.S. investments funds are interested in French companies, which seemingly shows the growing appeal of our innovations. This is an excellent opportunity for Genticel to present to the U.S. investors our portfolio of therapeutic vaccines in development that will contribute to the fight against cervical cancer of the uterus,” states Benedikt Timmerman.

Pierre-Olivier Goineau, the President of France Biotech, explains: “We are delighted by the high level of interest shown for “French Life Sciences Days,” which will take place for the first time in New York with the U.S. financial community (…) Our companies were born with an international dimension, and they develop breakthrough innovations that are increasingly attractive to foreign investors. This first edition is intended to be replicated in countries where it will be important for our companies to showcase their innovations and breakthroughs”
 

More information on the “French Life Sciences Days” on:

http://conf.france-biotech.org/france-biotech/french-conf

Genticel will also participate during the following months in various meetings with investors to present to them its development strategy:

Financial calendar (after stock exchange closing):

More information about Genticel is available on:
www.genticel.com under the ‘Investors' tab

About Genticel
Genticel is a French pharmaceutical company specializing in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer. Genticel is developing the first-ever therapeutic vaccine, currently in a phase II clinical trial, aimed at eliminating cells infected by HPV virus type 16 and/or 18. A second therapeutic vaccine candidate targeting six of the most pertinent strains of HPV is currently in preclinical stage. Over many years of R&D, the company has also produced Vaxiclase, a technology platform ideally adapted for developing early-intervention immunotherapies against multiple infectious or cancerous diseases.

Based in Paris and Toulouse, Genticel was awarded the 2013 Innovation Prize by the Grands Prix de l'Economie.

Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.

For more information, visit genticel-bourse.com